35 results about "Neuroblast" patented technology

The invention discloses a family of peptides termed NRP compounds or NRPs that can promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation and / or neuronal survival, and provides compositions and methods for the use of NRPs in the treatment of brain injury and neurodegenerative disease. NRP compounds can induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as exposure to toxins, stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient. NRP compounds can be formulated into pharmaceutically acceptable dose forms for therapeutic use. Methods for detecting neural regeneration, neural proliferation, neural differentiation, neurite outgrowth and neural survival can be used to develop other neurally active agents.

The invention discloses a family of peptides termed NRP compounds or NRPs that can promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation and / or neuronal survival, and provides compositions and methods for the use of NRPs in the treatment of brain injury and neurodegenerative disease. NRP compounds can induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as exposure to toxins, stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient. NRP compounds can be formulated into pharmaceutically acceptable dose forms for therapeutic use. Methods for detecting neural regeneration, neural proliferation, neural differentiation, neurite outgrowth and neural survival can be used to develop other neurally active agents.

The present invention relates to a method for differentiating a neural stem cell into a neuronal cell such as a neuroblast or a neuron in vitro or in vivo. Particularly, the invention provides for a method for neural stem cell differentiation by contacting the neural stem cell with a 5HT1A ligand or agonist.

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

The present invention relates to a neuronal differentiation method of adult stem cells using small molecules, more particularly to a method for inducing differentiation of adult stem cells into nerve cells using small molecules, which enables effective differentiation into nerve cells and, thus, is useful in treating intractable CNS disorders such as Parkinson's disease, dementia, Alzheimer's disease and spinal cord injury.

Provided is a composition for treating nerve damage-related diseases. The composition includes a human umbilical cord blood-derived mesenchymal stem cell as an active ingredient. The mesenchymal stem cell isolated and incubated from the human umbilical cord blood migrates to an injured area to be differentiated into a nerve cell or a neuroglial cell at the time of in vivo transplantation. Thus, the mesenchymal stem cell and a composition including the same can be effectively used in cell replacement therapy and gene therapy for treating diseases caused by nerve damage including a stroke, Parkinson's disease, Alzheimer's disease, Pick's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic central nervous system disease and a spinal cord injury.

The present invention relates to a method for differentiating a neural stem cell into a neuronal cell such as a neuroblast or neuron in vitro or in vivo. Particularly, the invention provides for a method for neural stem cell differentiation by contacting the neural stem cell with a valproate compound or analog thereof.

The invention discloses a method for inducing and differentiating a human embryonic stem cell into nerve cells. The method comprises the following steps of: separating and purifying a human embryonic stem cell to obtain human embryonic stem cell monomers; and inoculating the human embryonic stem cell monomers according to the cell density of (1-5)*104 / cm<2>, and performing single-layer adherence induced culturing, wherein in the induced culturing, nerve cells are obtained by pre-inducing the human embryonic stem cell with a sodium butyrate and an inducting culture medium I and performing differentiated induced culturing with an inducing culture medium. According to the method, the defects of high nerve cell heterogeneous degree, low differentiating efficiency, inconvenience for observing and operating in real time, need of a subsequent sorting process and the like existing in the conventional differentiating method can be overcome; the method has the advantages of easiness and convenience for operating, short inducting period (10-12) days, high nerve cell uniformity (the ratio is over 85 percent), and the like; and according to electrophysiologic monitoring, the nerve cells have convulsion discharging functions.

The invention belongs to the technical field of stem cell induction differentiation, particularly relates to an inducer and an induction medium, and discloses an inducer and induced differentiation complete medium for inducing mesenchymal stem cells into nerve cells. The inducer for inducing the mesenchymal stem cells into the nerve cells comprises resveratrol, icariin, hydrocortisone, VEGF, IGF-I and EPO. Every one thousand milliliters of the induced differentiation complete medium for inducing the mesenchymal stem cells into nerve cells comprises 30-50 micromoles of resveratrol, 5-10 micromoles of icariin, 5-10 micromoles of hydrocortisone, 10-20 micrograms of VEGF, 5-10 micrograms of IGF-I, 2-5 micrograms of EPO and the balance mesenchymal stem cell serum-free complete media. According to the induced differentiation complete medium for inducing the mesenchymal stem cells into the nerve cells, the traditional Chinese medicine ingredients of resveratrol and icariin are combined with hydrocortisone and the growth factors of VEGF, IGF-I and EPO to synergistically induce the mesenchymal stem cells to be directionally differentiated into the nerve cells, and the selected induction components are all free of poison, high in induction efficiency, short in induction time, good in activity of the nerve cells obtained through induction, free of rejection after cell transplantation, free of ethical issues and high in safety.

The present invention provides a method of differentiating and proliferating a mesenchymal stem cell into the neural cell by culturing in a medium comprising an epidermal growth factor and a hepatocyte growth factor after confluent culture of the mesenchymal stem cell. The present invention provides more effective method of differentiating and proliferating the mesenchymal stem cell or the mononuclear cell comprising the mesenchymal stem cell into the neural cell with a neuron and an astrocyte in terms of time, efficiency and maturity as compared with conventional methods.

The invention discloses a family of neuronal migration-inducing, proliferation-promoting and neurite outgrowth promoting factors, termed NRP compounds, and provides compositions and methods for the use of NRP compounds in the treatment of brain injury and neurodegenerative disease. NRP compounds induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient.

This invention relates to multipotent stem cells, purified from the peripheral tissue of mammals, and capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.

This invention provides a method for regulating migration of neuronal progenitor cells in the nervous system of a mammal. The method comprises providing a mammal with TNR, a biologically active fragment of TNR, or a TNR agonist in an amount sufficient to direct migration of the neuronal progenitor cells. The invention provides a method of treating neurological diseases by replenishing diseased, damaged, or destroyed neural cells in the central nervous system or in the peripheral nervous system.

The invention relates to methods for inducing marrow stromal cells to differentiate into neural cells by way of increasing intracellular levels of cyclic AMP. The invention also encompasses methods of producing a neural cell by causing a marrow stromal cell to differentiate into a neural cell by increasing intracellular levels of cyclic AMP. Methods for treating a human patient in need of neural cells are also disclosed, as well as methods for treating a human patient having a disease, condition, or disorder of the central nervous system.

Process for inducing differentiation of mesenchymal stamina cells into neuroblasts and / or neurons that envisions the use of a differentiation solution consisting of retinoic acid and ethanol.

The invention discloses a phenolic amide I, and an extraction method and an application thereof. The compound has a structure as shown in a formula (I) in the specification. The compound and a composition thereof have an obvious protecting action on cellular damage of human neuroblast (SH-SY5Y) induced by MPP+. The compound can be used as a drug for preventing and treating Parkinson's disease and has a good research and development prospect.

The invention relates to methods for inducing marrow stromal cells to differentiate into neural cells by way of increasing intracellular levels of cyclic AMP. The invention also encompasses methods of producing a neural cell by causing a marrow stromal cell to differentiate into a neural cell by increasing intracellular levels of cyclic AMP. Methods for treating a human patient in need of neural cells are also disclosed, as well as methods for treating a human patient having a disease, condition, or disorder of the central nervous system.

The present invention relates to a method of differentiating mesenchymal stem cells or adult stem cells into nerve cells by treating the mesenchymal stem cells or the adult stem cells with an electromagnetic field having a high intensity of 100 to 1,500 mT and a low frequency of 0.01 to 100 Hz. The present invention also relates to a medical device to which the method is applied. The method of differentiating nerve cells by using a magnetic field, and a composition according to the present invention induce the differentiation of adult stem cells into nerve cells by using a low-frequency, high-intensity electromagnetic field, so that nerve cells or neural stem cells can easily be differentiated through only electromagnetic field treatment in a short time.

This invention is in the field of medical molecular diagnostics. It provides methods and means for the in vitro detection of the neurodevelopmental toxicity of a compound by determining the gene expression of a limited number of genes. More in particular, it relates to a method for determining the likelihood that a compound is neurodevelopmental toxic, comprising the steps of: providing embryonic stem cells, allowing the stem cells to form embryoid bodies, allowing the embryoid bodies to differentiate into neural cells, in the presence of said compound, thereby creating a neural differentiation culture, extracting total RNA from the cells in said neural differentiation culture, determining the expression levels of genes Hoxb6, Nrk, 1700011H14Rik and Tph1, comparing the expression levels with a predetermined reference value and determining the increase or decrease of the expression level relative to the reference value, wherein a relative increase or decrease in expression value of more than 20% indicates that a compound is neurodevelopmental toxic.

An in vitro human neural multipotent, unipotent, or somatic cell possessing all of the following characteristics: is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; is not differentiated from a pluripotent cell; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a neural stem cell, neural precursor cell, neural progenitor cell, neuroblast, or neuron; is not a cancerous cell; is stable and not artificially maintained by forced gene expression and may be maintained in standard neural stem cell media or neural media; and does not exhibit uncontrolled growth, teratoma formation, and tumor formation in vivo; wherein the cell comprises at least one polypeptide or an expression vector encoding at least one polypeptide selected from the group consisting of: Musashi1 (Msi1); Ngn2; Msi1 and Ngn2; Msi1 and methyl-CpG binding domain protein 2 (MBD2); Ngn2 and MBD2; Msi1, Ngn2 and MBD2; Achaete-Scute Homolog 1 (Ascl1); Msi1, Ngn2 and Ascl1; Msi1, Ngn2, MBD2 and Ascl1; Sox2; Msi1, Ngn2 and Sox2; and Msi1, Ngn2, MBD2 and Sox2; wherein the expression vector is transiently expressed.

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

The invention discloses a family of neuronal migration-inducing, proliferation-promoting and neurite outgrowth promoting factors, termed NRP compounds, and provides compositions and methods for the use of NRP compounds in the treatment of brain injury and neurodegenerative disease. NRP-1 compounds induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient.

The invention relates to a rat pancreas islet epithelioid stem cell system and belongs to the field of animal cell (tissue) engineering. The rat pancreas islet epithelioid stem cell is from a normal adult rat pancreas islet tissue, cultured in vitro, and can grow in a clonal manner; moreover, the cell has a plurality of differentiation potentials, specifically cell adherent culture is polygonal and epithelioid, cell nucleus is oval, and nucleolus is a single nucleolus or amphinucleolus; in cell clonal growth, cells grow slowly on the first day after being inoculated, enter a logarithm growth period on the second day to the fourth day and enter a platform period on the fifth day to the sixth day, and multiplication capacity is reduced on the seventh day; the cells are normal diploid cells with a chromosome number 2n equal to 42; an octamer transcription factor 4, a paired-gene cassette 4, paired-gene cassette 6, a neurogenic factor 3 and nidogen are expressed on protein level. The rat pancreas islet epithelioid stem cell system has the plurality of differentiation potentials, is directionally induced in vitro to differentiate and form nerve cells, fat cells and osteoblast, and is free of oncogenicity.

The invention belongs to the technical field of stem cell induction differentiation, particularly relates to an inducer and an induction medium, and discloses an inducer and induced differentiation complete medium for inducing mesenchymal stem cells into nerve cells. The inducer for inducing the mesenchymal stem cells into the nerve cells comprises resveratrol, icariin, hydrocortisone, VEGF, IGF-I and EPO. Every one thousand milliliters of the induced differentiation complete medium for inducing the mesenchymal stem cells into nerve cells comprises 30-50 micromoles of resveratrol, 5-10 micromoles of icariin, 5-10 micromoles of hydrocortisone, 10-20 micrograms of VEGF, 5-10 micrograms of IGF-I, 2-5 micrograms of EPO and the balance mesenchymal stem cell serum-free complete media. According to the induced differentiation complete medium for inducing the mesenchymal stem cells into the nerve cells, the traditional Chinese medicine ingredients of resveratrol and icariin are combined with hydrocortisone and the growth factors of VEGF, IGF-I and EPO to synergistically induce the mesenchymal stem cells to be directionally differentiated into the nerve cells, and the selected induction components are all free of poison, high in induction efficiency, short in induction time, good in activity of the nerve cells obtained through induction, free of rejection after cell transplantation, free of ethical issues and high in safety.

The present invention is aimed at providing a method for utilizing external gene operation to induce the intracerebral transplanted mesenchymal stem cell to implement directed differentiation and make it into neurone. Its technical scheme includes the following steps: (1). using self-body biological characteristics to separate, amplify the purify mesenchymal stem cell; (2). cloning brain-derived neurotrophic factor cDNA sequence from human neuroblast tumor cDNA library, constructing retroviral vector of recombinant human brain-derived neurotrophic factor gene and introducing the brain-derived neutrotrophic factor gene into mesenchymal stem cell; and (3). utilizing cerebral stereo-orientation method to make the mesenchymal stem cell modified by brain-derived neurotrophic factor gene be transplanted into brain. Under the induction of neurotrophic factor the ratio of defferentiating mesenchymal stem cell into neurone can be obviously raised. Said invention also provides its application value.

The present invention belongs to the field of cell transplantation. Particularly, the present invention provides a method of producing neurons for treating injuries with the loss of neuron function from stem cells, wherein the stem cell is a human derived mesenchymal stem cell, preferably human derived placental mesenchymal stem cell, bone marrow mesenchymal stem cell, adipose mesenchymal stem cell and liver mesenchymal stem cell. The present invention also provides the uses of said method and the nerve cells produced by said method in the preparation of medicines for treating injuries with the loss of neuron function and in the treatment of injuries with the loss of neuron function. The present invention further provides a method of treating injuries with the loss of neuron function.

Process for inducing differentiation of mesenchymal stamina cells into neuroblasts and / or neurons that envisions the use of a differentiation solution consisting of retinoic acid and ethanol.

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

This invention relates to multipotent stem cells, purified from the peripheral tissue of mammals, and capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.